Preparation and characterization of co-processed starch/MCC/chitin hydrophilic polymers onto magnesium silicate

Assaf, Shereen M.; Khanfar, Mai; Farhan, Ahmed Bassam; Rashid, Iyad; Badwan, Adnan A.

doi:10.1080/10837450.2019.1596131

Cited by 8 publications

(4 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The parameters of weight, thickness, and hardness of tablets were measured using a balance (UWE serial no 136271/05), Micrometer (Mitutoyo Tokyo, Japan), and Tablet Tensile Analyser (TTA 331-1750, London, UK), respectively, and used to compute the volume [4], apparent density [14], and relative density (D) [15] of the tablets from the equations below:…”

Section: True Densitymentioning

confidence: 99%

“…The development of novel excipients by co-processing has witnessed a surge in the last few decades. Coprocessing as a particle engineering technique has proven to be a useful strategy in improving the functionality or performance of existing single component excipients like lactose [1], microcrystalline cellulose [2], and starch [3,4]. Some of the functionality improvements so far recorded with co-processed excipients include enhanced flowability, compressibility, dilution potential, lubricant sensitivity, stability, moisture sensitivity, superdisintegrating ability, etc.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Compaction and tableting properties of composite particles of microcrystalline cellulose and crospovidone engineered for direct compression

Haruna

Apeji

Oparaeche³

et al. 2020

Futur J Pharm Sci

View full text Add to dashboard Cite

Background: Excipients with improved functionality have continued to be developed by the particle engineering strategy of co-processing. The aim of this study was to evaluate the compaction and tableting properties of composite particles of microcrystalline cellulose (MCC) and crospovidone (CPV) engineered by co-processing. Results: Heckel analysis of the compaction behavior revealed a decrease in plasticity of co-processed excipient (CPE) when compared to MCC due to an increase in Heckel yield pressure from 144 to 172 MPa. The compressibility-tabletability-compactibility (CTC) profile revealed a decrease in individual parameters for CPE when compared to MCC. CPE was found to be more sensitive to the lubricant effect of sodium stearyl fumarate (SSF) when compared to MCC and less sensitive to magnesium stearate (MST) when compared to MCC. A higher dilution potential was obtained for MCC (60%) compared to 44% for CPE when metronidazole was used as model drug. Tableting properties revealed that metronidazole tablets generated with CPE by direct compression disintegrated within 15 min and gave a rapid drug release when compared to MCC as a direct compression (DC) excipient. Conclusion: The compaction and tableting properties of CPE were characterized and yielded tablets with better disintegration and drug release profile when compared to MCC. This study, therefore, confirms the suitability of co-processing as a proven strategy in engineering the performance of excipients.

show abstract

Section: True Densitymentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Compaction and tableting properties of composite particles of microcrystalline cellulose and crospovidone engineered for direct compression

Haruna

Apeji

Oparaeche³

et al. 2020

Futur J Pharm Sci

View full text Add to dashboard Cite

show abstract

“…[21] Nearly 70-80% of pharmaceutical dosage forms contain higher numbers and concentrations of pharmaceutical excipients. [22] Higher concentration of excipients likely affects the functional properties and processability/method of preparation of tablets. [23] Compared to wet and dry granulation, the direct compression method (DCM) is the most efficient method for the preparation of the tablet due to the involvement of only preparation and then compression of a dry mixture of API and excipient using a tablet compression machine.…”

Section: Review Articlementioning

confidence: 99%

“…It also enhanced crushing strength, disintegration time, and rapid drug dissolution from the tablet. [22] Semisolid dosage forms Semisolid dosage forms are the most significant portion of pharmaceutical products. However, some solid excipients have poor physicochemical characteristics, which decreases the integrity of the final formulations.…”

Section: Oral Solid Dosage Formsmentioning

confidence: 99%

Untitled

2023

AJP

View full text Add to dashboard Cite

In pharmaceutical dosage forms, the excipient represents a unique and significant substance with equal importance to active pharmaceutical ingredients (API) because it offers numerous benefits to the final formulations. Benefits include filling the tablet's total volume, enhancing API absorption and bioavailability, and increasing organoleptic properties. However, the diverse nature of excipients, API-excipients incompatibility, moisture absorbing ability, surface acidity of the excipients, crystal nature, and generation of inferior toxic excipients, etc., may create a big problem in selecting appropriate excipients. The excipients high toxicity may substantially impact the formulation and API's pharmacokinetic and pharmacodynamic nature. It may likely be due to using multiple excipients with incompatible performance. Adopting and implementing cGMP in the pharmaceutical industry can solve the issues related to excipients; however, it still affects the excipients manufacturing process in terms of its time-consuming, high cost, and lengthy approval process. With their multifunctional properties, coprocessed excipients can provide special offers to formulation scientists when manufacturing dosage forms. The need for coprocessed excipients, requirements of excipients to be coprocessed, manufacturing technology, risk and assessment studies, application, and regulatory compliance provide an alternate and promising approach for selecting and using an appropriate combination of existing excipients over the native excipients in the formulation of dosage forms.

show abstract